|
|
||||||||

* Columbus Childrens Research Institute and Department of Pediatrics, Ohio State University College of Medicine and Public Health, Columbus, OH 43205; and
Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892
Respiratory syncytial virus (RSV) is the major cause of severe lower airway disease in infants and young children, but no safe and effective RSV vaccine is yet available. The difficulties involved in RSV vaccine development were recognized in an early vaccine trial, when children immunized with a formalin-inactivated virus preparation experienced enhanced illness after natural infection. Subsequent research in animal models has shown that the vaccine-enhanced disease is mediated at least in part by memory cells producing Th2 cytokines. Previously we had observed enhanced, eosinophilic lung pathology during primary infection of IFN-deficient STAT1/ mice that are incapable of generating Th1 CD4+ cells. To determine whether these effects depended only on Th2 cytokine secretion or involved other aspects of IFN signaling, we infected a series of 129SvEv knockout mice lacking the IFN-
R (IFN-
R/), the IFN-
R (IFN-
R/), or both receptors (IFN-

R/). Although both the IFN-
R/ and the IFN-

R/ animals generated strong Th2 responses to RSV-F protein epitopes, predominantly eosinophilic lung disease was limited to mice lacking both IFNRs. Although the absolute numbers of eosinophils in BAL fluids were similar between the strains, very few CD8+ T cells could be detected in lungs of IFN-

R/ animals, leaving eosinophils as the predominant leukocyte. Thus, although CD4+ Th2 cell differentiation is necessary for the development of allergic-type inflammation after infection and appears to be unaffected by type I IFNs, innate IFNs clearly have an important role in determining the nature and severity of RSV disease.
Related articles in The JI:
This article has been cited by other articles:
![]() |
B. Kapitein, M. O. Hoekstra, E. H. J. Nijhuis, D. J. Hijnen, H. G. M. Arets, J. L. L. Kimpen, and E. F. Knol Gene expression in CD4+ T-cells reflects heterogeneity in infant wheezing phenotypes Eur. Respir. J., November 1, 2008; 32(5): 1203 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Castilow, M. R. Olson, D. K. Meyerholz, and S. M. Varga Differential Role of Gamma Interferon in Inhibiting Pulmonary Eosinophilia and Exacerbating Systemic Disease in Fusion Protein-Immunized Mice Undergoing Challenge Infection with Respiratory Syncytial Virus J. Virol., March 1, 2008; 82(5): 2196 - 2207. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Scagnolari, F. Midulla, S. Trombetti, A. Pierangeli, V. Tromba, R. Grossi, P. Di Marco, C. Dianzani, E. Girardi, and G. Antonelli A BRIEF COMMUNICATION: Upregulation of Interferon-Induced Genes in Infants with Virus-Associated Acute Bronchiolitis Exp Biol Med, November 1, 2007; 232(10): 1355 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Jewell, N. Vaghefi, S. E. Mertz, P. Akter, R. S. Peebles Jr., L. O. Bakaletz, R. K. Durbin, E. Flano, and J. E. Durbin Differential Type I Interferon Induction by Respiratory Syncytial Virus and Influenza A Virus In Vivo J. Virol., September 15, 2007; 81(18): 9790 - 9800. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Janssen, J. Pennings, H. Hodemaekers, A. Buisman, M. van Oosten, L. de Rond, K. Ozturk, J. Dormans, T. Kimman, and B. Hoebee Host Transcription Profiles upon Primary Respiratory Syncytial Virus Infection J. Virol., June 1, 2007; 81(11): 5958 - 5967. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Melendi, S. J. Hoffman, R. A. Karron, P. M. Irusta, F. R. Laham, A. Humbles, B. Schofield, C.-H. Pan, R. Rabold, B. Thumar, et al. C5 Modulates Airway Hyperreactivity and Pulmonary Eosinophilia during Enhanced Respiratory Syncytial Virus Disease by Decreasing C3a Receptor Expression J. Virol., January 15, 2007; 81(2): 991 - 999. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Riffault, C. Dubuquoy, N. Castagne, E. Baranowski, B. Charley, and J.-F. Eleouet Replication of Bovine respiratory syncytial virus in murine cells depends on type I interferon-receptor functionality. J. Gen. Virol., August 1, 2006; 87(Pt 8): 2145 - 2148. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kotelkin, I. M. Belyakov, L. Yang, J. A. Berzofsky, P. L. Collins, and A. Bukreyev The NS2 Protein of Human Respiratory Syncytial Virus Suppresses the Cytotoxic T-Cell Response as a Consequence of Suppressing the Type I Interferon Response J. Virol., June 15, 2006; 80(12): 5958 - 5967. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Smit, B. D. Rudd, and N. W. Lukacs Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus J. Exp. Med., May 15, 2006; 203(5): 1153 - 1159. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Martinez-Sobrido, N. Gitiban, A. Fernandez-Sesma, J. Cros, S. E. Mertz, N. A. Jewell, S. Hammond, E. Flano, R. K. Durbin, A. Garcia-Sastre, et al. Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector J. Virol., February 1, 2006; 80(3): 1130 - 1139. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Holtzman, J. W. Tyner, E. Y. Kim, M. S. Lo, A. C. Patel, L. P. Shornick, E. Agapov, and Y. Zhang Acute and Chronic Airway Responses to Viral Infection: Implications for Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, August 1, 2005; 2(2): 132 - 140. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |